Final combined fill volume [pending] · Pack imagery represents current concept and is subject to change.
AUREVIA CD//CARDIO+
Multi-pathway cardiovascular wellness, delivered through two precisely separated phases.
AUREVIA CD//CARDIO+ expands the foundational DualPhase™ platform with a selected group of cardiovascular-wellness ingredients — α-CD, HPβCD, aged garlic extract, ubiquinol CoQ10, vitamin K2 as MK-7, tocotrienols, magnesium taurate, taurine and pomegranate polyphenols. Intended to support a comprehensive daily routine across lipid metabolism, mitochondrial energy, antioxidant protection, normal calcium utilisation and vascular wellness.
Not available for purchase until finished-product validation is complete.
Cyclodextrin intelligence. Liposomal precision.
Each daily unit contains two connected chambers — a purified aqueous cyclodextrin matrix and a separately manufactured phospholipid phase — combined only at the moment of use.
Phase One — Cyclodextrin & Water-Soluble Matrix
- α-CyclodextrinValidated quantity pending
- Digestive-phase lipid interaction
- Soluble-fibre-style component
- Complementary gut-phase pathway
- HPβCDPending regulatory & safety review
- Advanced cyclodextrin-research component
- Cholesterol-inclusion research platform
- Analytical investigation of free/exchangeable fractions
- Standardised aged garlic extract
- Vascular-wellness support
- Antioxidant support
- Ingredient-level cardiovascular differentiation
Randomised coronary-CT studies reported low-attenuation plaque changes at ingredient level. Not evidence that the finished product will produce the same result.
- Magnesium taurate
- Magnesium intake
- Normal muscle & nerve function
- Electrolyte support
Elemental magnesium will be declared on final label.
- Taurine
- Cellular osmotic balance
- Complementary cardiovascular-wellness positioning
- Standardised pomegranate extract
- Polyphenol content
- Antioxidant formulation support
- Vascular-wellness positioning
Human evidence mixed. Meta-analysis found no clear lipid effect.
Phase Two — Liposomal Cardiovascular Matrix
- Ubiquinol CoQ10
- Mitochondrial-energy support
- Lipid-phase antioxidant
- Delivered through a lipid-compatible matrix
Requires verified assay, oxidation & light protection across shelf life.
- Vitamin K2 as MK-7
- Supports normal calcium utilisation
- Supports normal vitamin-K-dependent protein function
Do not use with warfarin or vitamin-K-sensitive anticoagulants unless approved by the prescribing clinician.
- Gamma- & delta-tocotrienols
- Vitamin E-family antioxidant system
- Lipid-phase protection
- Differentiation from conventional alpha-tocopherol formulas
- Sunflower phosphatidylcholine
- Liposomal carrier
- Disperses lipid-soluble ingredients
- Separates fat-soluble co-actives from the cyclodextrin matrix
- Natural mixed tocopherols
- Oxidative protection of the phospholipid phase
- Shelf-life support
Designed to support.
Proposed structure/function positioning. Requires final formulation-specific substantiation and regional regulatory approval.
- Healthy lipid metabolism
- Cardiovascular wellness
- Mitochondrial energy production
- Antioxidant defence
- Normal calcium utilisation
- Vascular wellness
- A structured cardiovascular-longevity routine
Cyclodextrin, lipid-phase actives and water-soluble botanicals across two dedicated chambers.
Ubiquinol CoQ10 delivered in a phospholipid-compatible matrix.
Gamma/delta tocotrienols, pomegranate polyphenols and aged garlic extract.
MK-7 to support normal calcium utilisation as part of the vascular-wellness system.
Nothing hidden.
Final quantities are declared once formulation and regulatory review are complete.
| Ingredient | Role | Per serving | Evidence |
|---|---|---|---|
| α-Cyclodextrin | Gut-phase cyclodextrin | TBC | Emerging |
| HPβCD | Advanced cyclodextrin research | TBC | Mechanistic |
| Aged garlic extract (standardised) | Vascular-wellness support | TBC | Emerging |
| Ubiquinol CoQ10 | Mitochondrial-energy support | TBC | Established |
| Vitamin K2 (MK-7) | Normal calcium utilisation | TBC | Established |
| Gamma/delta tocotrienols | Lipid-phase antioxidant | TBC | Emerging |
| Magnesium taurate | Elemental magnesium | TBC | Established |
| Taurine | Cellular osmotic balance | TBC | Emerging |
| Pomegranate extract (standardised) | Polyphenol antioxidant | TBC | Emerging |
| Sunflower phosphatidylcholine | Cholesterol-free liposomal carrier | TBC | Established |
The flagship AUREVIA cardiovascular-wellness system.
Water-soluble cyclodextrins and botanicals stay in Phase One; lipid-soluble actives stay in Phase Two — combined only at the moment of use.
Each active is defined by standardised marker, verified assay, supplier identity, batch data and stability requirements.
Ingredient-level human research is cited where it exists — never presented as finished-product clinical proof.
- Adults building a structured cardiovascular-longevity routine
- Consumers who already use CoQ10 or K2 and are looking for an integrated delivery format
- Practitioners evaluating multi-pathway cardiovascular-wellness formats
- Early adopters interested in advanced formulation technology
Consult a qualified healthcare professional before use if you:
- Are pregnant or breastfeeding
- Take prescription medication
- Have kidney or liver disease
- Have diagnosed cardiovascular disease
- Use lipid-lowering medication
- Are receiving specialist medical care
- Are preparing for surgery or another medical procedure
- Have experienced sensitivity to cyclodextrins or formulation ingredients
Do not discontinue or replace prescribed treatment.
Questions we get, answered honestly.
Will CD//CARDIO+ replace my cardiovascular medication?+
No. It is not a treatment for cardiovascular disease and does not replace prescribed medication. Discuss any change to treatment with your prescribing clinician.
Can I use it with warfarin?+
Not without specific clearance from the prescribing clinician. MK-7 can interact with vitamin-K-sensitive anticoagulants.
Is the finished product clinically tested?+
Not yet. Ingredient-level research is not the same as a finished-product trial. Studies are planned.
Why keep CoQ10 separated from the cyclodextrins?+
To limit prolonged pre-use interaction between cyclodextrins and lipid-soluble actives, and to protect ubiquinol from premature oxidation.
The rest of the DualPhase™ collection.
Dual-cyclodextrin lipid pathway formula. The foundation of the AUREVIA DualPhase™ platform.
Practitioner circulation system supporting endothelial wellness, nitric-oxide pathways and fibrinolytic balance.